Background and Purpose: The high potency antipsychotic drug trifluoperazine (10-[3-(4-methyl-1-piperazinyl)-propyl]-2-(trifluoromethyl)-(10)H-phenothiazine dihydrochloride; TFP) may either counteract or promote suicidal cell death or apoptosis. Similar to apoptosis, erythrocytes may enter eryptosis, characterized by phosphatidylserine exposure at the cell surface and cell shrinkage. Eryptosis can be stimulated by an increase in cytoplasmic Ca2+ concentration ([Ca2+]i) and inhibited by nitric oxide (NO). We explored whether TFP treatment of erythrocytes induces phosphatidylserine exposure, cell shrinkage, and calcium influx, whether it impairs S-nitrosylation and whether these effects are inhibited by NO. Methods: Phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, and protein nitrosylation from fluorescence switch of the Bodipy-TMR/Sypro Ruby signal. Results: Exposure of human erythrocytes to TFP significantly enhanced the percentage of annexin-V-binding cells, raised [Ca2+]i, and decreased S-nitrosylation. The effect of TFP on annexin-V-binding was not affected by removal of extracellular Ca2+ alone, but was significantly inhibited by pre-treatment with sodium nitroprusside (SNP), an effect significantly augmented by additional removal of extracellular Ca2+. A 3 hours treatment with 0.1 µM Ca2+ ionophore ionomycin triggered annexin-V-binding and cell shrinkage, effects fully reversed by removal of extracellular Ca2+. Conclusions: TFP induces eryptosis and decreases protein S-nitrosylation, effects blunted by nitroprusside. The effect of nitroprusside is attenuated in the presence of extracellular Ca2+.

Trifluoperazine (10-[3-(4-methyl-1-piperazinyl)-propyl]-2-(trifluoromethyl)-(10) H-phenothiazine dihydrochloride; TFP) [1], a high potency antipsychotic drug used for the treatment of schizophrenia and schizophrenia-like conditions [2-4], has further been used as analgesic in patients with neuropathic pain due to sickle cell disease [5].

Side effects of TFP include movement disorders [2-5] and sedation [5]. TFP is effective in part by reorganization of the cytoskeletal architecture [6], binding to and inhibiting of Ca2+/calmodulin [7, 8], which affects numerous proteins in the erythrocytes [9], including the plasma membrane Ca2+ pump [10] and eNOS [9]. Further interaction partners of TFP include protein kinase IIα [5, 11], Wnt/β-catenin signaling [12], and DNA-dependent protein kinase [13]. TFP may depolymerize actin filaments [14], decrease Bcl-2 and increase Bax protein abundance [14]. Moreover, TFP increases early growth response gene-1 (Egr-1) expression [15] and the phosphorylation of ERK and JNK [14]. TFP inhibits P-glycoprotein expression [16].

Depending on the cell type, TFP counteracts oxidative stress by decreasing the formation of reactive oxygen species (ROS), thus preventing ROS-induced mitochondrial depolarization and protecting against apoptosis [17]. Along those lines TFP supports survival of T lymphocytes [1]. On the contrary, TFP may induce or augment apoptosis, especially of cancer cells [13, 14, 18, 19]. TFP inhibits cancer stem cell proliferation [12] and is effective against various malignancies including lung cancer [12-14], glioma [15], and leukemia [16]. Taken together, the effects of TFP on apoptotic pathways largely depend on the identity of the cell and/or on the cellular context.

In analogy to nucleated cell apoptosis, erythrocytes may enter eryptosis [20, 21], the suicidal death of erythrocytes characterized by cell shrinkage [22] and cell membrane scrambling with phosphatidylserine translocation to the cell surface [20]. Eryptosis may be triggered by an increase in cytosolic Ca2+ ([Ca2+]i)[20]. Further stimulators of eryptosis include ceramide [23, 24], oxidative stress [20], energy depletion [20], activated caspases [20, 25, 26], stimulated activity of casein kinase 1α, Janus-activated kinase JAK3, protein kinase Cα, p38 kinase and PAK2 kinase [20], impaired activity of AMP activated kinase AMPK, cGMP-dependent protein kinase, and sorafenib/sunitinib sensitive kinases [20] and/or exposure to a wide variety of xenobiotics [20, 27-41]. Inhibitors of eryptosis include erythropoietin [42] and nitric oxide [43].

The present study explored whether TFP induces eryptosis and, if so, to test whether the effect is sensitive to NO. Furthermore, the influence of a combination of extracellular Ca2+ removal and pre-treatment with the NO donor sodium nitroprusside (SNP) on eryptosis was studied.

Erythrocytes

Highly purified erythrocyte suspensions from healthy volunteers with white blood cell (WBC) or thrombocyte contaminations below 0.1 % [44] were provided by the blood bank of the University of Tübingen. Aliquots of the individual erythrocyte concentrates were either used directly at 0.4% hematocrit (Hct) or stored at 4°C for up to one week. The study was approved by the ethics committee of the University of Tübingen, the study was performed in agreement with the declaration of Helsinki, and volunteers gave written consent (184/2003 V).

Solutions and chemicals

Experiments analysing annexin-V-binding of erythrocytes and cell volume (0.4% Hct) as well as determination of cytosolic Ca2+ activity (0.1% Hct) were carried out in Ringer solution. Loading of erythrocytes (0.2% Hct) with 4 µM FLUO3/AM was performed in Fluo wash buffer. Staining of erythrocytes with annexin-V-FLUOS was performed in annexin binding buffer. Ringer solution was composed of (in mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 32 N-2-hydroxyethyl-piperazine-N´-2-ethanesulfonic acid (HEPES)/NaOH (pH 7.4), 5 glucose, and 1 CaCl2. Annexin-binding buffer contained (in mM): 125 NaCl, 10 HEPES/NaOH (pH 7.4), and 5 CaCl2. Fluo loading buffer contained (in mM): 123 NaCl, 5 KCl, 1 MgSO4, 25 HEPES/NaOH (pH 7.4), 10 glucose, 2 CaCl2, and 10 sodium pyruvate. 50 mg trifluoperazine (10-[3-(4-methyl-1-piperazinyl)-propyl]-2-(trifluoromethyl)-(10)H-pheno-thiazine dihydrochloride, TFP) was dissolved in 10.4 ml DMSO to achieve a 10 mM stock solution. This stock was subsequently aliquoted in 250 µl units and stored at -20 °C for up to 3 months. Where indicated, trifluoperazine.2 HCl (TFP: 1 - 20 µM) was added. Dimethylsulfoxide (DMSO)-treated erythrocytes served as solvent controls (0.2% (v/v) DMSO). DMSO and sodium nitroprusside were purchased from Sigma (Taufkirchen, Germany). TFP and annexin V-FLUOS were purchased from Selleckchem (USA) and Roche Diagnostics (Mannheim, Germany), respectively. FLUO3/AM and CM-H2DCFDA were purchased from Calbiochem (Germany) and Invitrogen (USA), respectively.

Phosphatidylserine exposure and forward scatter

Erythrocyte concentrates suspended in 2 ml Ringer solution (0.4% Hct) were treated in the absence or presence of TFP for 24 hours. After incubation under the respective experimental condition, 100 µl cell suspension (2·106 erythrocytes) were washed in 500 µl annexin-binding buffer. Erythrocyte pellets were then vortexed gently to achieve a homogenous cell suspension. To detect phosphatidylserine (PS) on the outer leaflet of the plasma membrane, the cells were subsequently stained with 32 µl annexin V-FLUOS at a 1:33 dilution and mixed gently on a vortex mixer. After 20 min incubation in the dark at room temperature, 200 µl of annexin-binding buffer was added to each sample, thoroughly vortexed to achieve single cell suspensions, and analysed by flow cytometry on a FACS-Calibur (Becton Dickinson, Heidelberg, Germany). Erythrocyte volume was determined by forward scatter (FSC). To this end, corresponding erythrocytes suspensions were immediately analysed by flow cytometry.

Hemolysis

Erythrocyte concentrates (0.4% Hct) were treated with varying concentrations of TFP for 24 hours, then hemolysis was determined. Briefly, after incubation, 600 µl suspension containing 1.2·107 erythrocytes were centrifuged for 4 min at 420 g, 4°C, and the supernatants were harvested. As a measure of hemolysis, the hemoglobin (Hb) concentration of the supernatants was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis.

Measurement of cytosolic Ca2+

Erythrocyte concentrates (0.2% Hct), suspended in 20 ml Fluo3 loading buffer were stained with Fluo3/AM at 4 µM final concentration. The cells were incubated at 37°C for 1 hour under shaking and protection from light. Excess dye was removed by washing erythrocytes twice with Fluo3 loading buffer and once with Ringer solution (6 min at 280 g, room temperature). For flow cytometry, Fluo3/AM-loaded erythrocytes (0.1% Hct) were resuspended in Ringer solution containing 0 – 20 µM TFP, or the Ca2+ ionophor ionomycin (0.25 µM) as a positive control, or vehicle alone (0.2% v/v) as a negative control. After incubation for different time periods at 37 °C, Ca2+-dependent fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur.

Fluorescence microscopy

For fluorescence microscopy, Fluo4/AM-loaded erythrocytes (0.1% Hct) suspended in Ringer solution were treated in the absence or presence of TFP for 1 hour, 3 hours, or 6 hours. The preparation of RBCs for microscopy experiments were the same as for flow cytometry measurements. Erythrocytes were monitored using an inverted fluorescence microscope (Eclipse TE2000-E, Nikon, Tokyo, Japan) as described before [45, 46]. The diluted erythrocyte samples (approximately 0.025% haematocrit) were placed on a cover slip in a dark room at room temperature. Images were taken with an electron multiplication CCD camera (CCD97, Photometrics, Tucson, USA) using a 100x1.4 (NA) oil immersion lens with infinity corrected optics. From each RBC sample, 5 images from different positions of the cover slip randomly chosen were taken using the imaging software VisiView (Visitron Systems, Puchheim, Germany). Each image consisted of one transmitted light (exposure time 200 ms) and one fluorescence shot (exposure time 4 s). Fluo-4 (instead of Fluo-3) has been used for Ca2+ imaging and was excited with a xenon lamp-based monochromator (Visitron Systems, Puchheim, Germany) at a centre wavelength of 488 nm. Emission was recorded at 520/15 nm. Fluo-4 AM was obtained from Molecular Probes (Eugene, USA).

Patch clamp experiments

Patch-clamp measurements were performed with a NPC-16 Patchliner (Nanion Technologies, Munich, Germany) [47]. The resistance of the chips was between 5 and 8MΩ with internal and external solutions as follows (in mM): KCl 70, KF 70, NaCl 10, HEPES 10, MgATP 2, EGTA 3 and CaCl2 1.2 to give 120nM free [Ca2+] i, pH=7.2 adjusted with KOH (internal) and NaCl 140, KCl 4, MgCl2 5, D-glucose 5, HEPES 10, CaCl2 2, pH=7.3 adjusted with NaOH (external). Gigaseals were considered successful if exceeding 5 GΩ (with most cells they were 10 GΩ and above). Gigaseal formation was facilitated by the use of a seal enhancing solution as recommended by the Patchliner manufacturer and containing (in mM): NaCl 80, KCl 3, MgCl2 10, CaCl2 35, HEPES 10, pH=7.3 adjusted with NaOH. Whole-cell configuration was achieved by negative pressure suction pulses between -45 mbar and -150 mbar and its formation judged by the appearance of sharp capacitive transients. Whole-cell patch-clamp recordings were conducted at room temperature using voltage steps from -100 mV to 80 mV for 500 ms in 20 mV increments at 5 s intervals, the holding potential being set at -30 mV. Assessment of the effect of TFP was carried out with 1 and 10 µM. To reduce inter-cell variability data are expressed as normalized current which is the ratio of the current under specified experimental conditions i.e. before (control) and in the presence of 1 and 10 µM TFP at selected membrane potentials, to the current at +80 mV determined 30–60 s before starting the control (control) measurement.

Fluorescence switch experiments for assessing S-nitrosylation

RBC concentrates (0.4% Hct) were treated with varying concentrations of TFP for 24 hours, with some samples pretreated with sodium nitroprusside (SNP) for 2 hours, and subjected to the fluorescence switch assay as previously described [48]; in brief, cells were lysed and blocked with N-ethylmaleimide, nitrosothiols reduced with ascorbate and newly formed thiols labelled with maleimide-Bodipy-TMR (Molecular Probes). A methodological control was performed by adding 1 mM S-nitroso-L-cysteine 15 min prior to erythrocyte lysis. Protein extracts subjected to the fluorescence switch were separated by SDS-PAGE, Bodipy-TMR signal was registered and the gels were stained with Sypro Ruby (Molecular Probes), following manufacturer’s instructions, for assessing total protein in each lane. Both signals were quantified using ImageQuant TL v7.0 software (GE Healthcare) and the ratio S-nitrosylation/total protein in each sample estimated from the Bodipy-TMR/Sypro Ruby ratio.

Statistical analysis

Data are presented as the mean values ± SEM of at least 3 independent experiments with different blood samples. A total of 23 different blood samples were used in this study. Unless otherwise stated, repeated measures one-way ANOVA with Dunnet’s post test was used for statistical comparisons of treated samples with controls. Differences of the means were considered to be statistically significant when the calculated p value was *P<0.05, **P<0.01, ***P<0.001, or ****P<0.0001.

Induction of eryptosis and cell shrinkage by trifluoperazine

The present study explored whether trifluoperazine (TFP) stimulates eryptosis, the suicidal erythrocyte death characterized by phosphatidylserine translocation to the cell surface, cell shrinkage and increased Ca2+ influx and, if so, to test whether these effects could be reversed by the nitric oxide donor sodium nitroprusside (SNP).

Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding and flow cytometry. Prior to measurements, erythrocytes were incubated for 24 hours in Ringer solution in the presence or absence of TFP (1 – 20 µM). As shown in Fig. 1A, B, exposure to TFP concentration-dependently increased the percentage of phosphatidylserine-exposing erythrocytes, an effect reaching statistical significance at 2.5 µM TFP. To study hemolytic effects of TFP, we determined the hemoglobin concentration in the supernatant of drug-treated erythrocytes. As illustrated in Fig. 1C, exposure to TFP increased the percentage of hemolytic erythrocytes. At 20 µM TFP, the hemolysis reached 11% after 24 hours (Fig. 1C).

Fig. 1.

Effect of trifluoperazine on phosphatidylserine exposure, hemolysis and cell volume. A) Original histogram of annexin-V-binding of erythrocytes treated for 24 hours with either DMSO (left panel, control) or with 5 µM (middle panel) or 10 µM (right panel) trifluoperazine, respectively. Numbers depict the geometric mean (GeoMean) of the annexin-V-FITC-dependent fluorescence of the different erythrocyte populations. B) Arithmetic means ± SEM (n = 3) of the percentage of annexin V binding erythrocytes after 24 hours incubation as a function of trifluoperazine concentrations (1 – 20 µM). C) Arithmetic means ± SEM (n = 3) of hemolysis (in % of maximal hemolysis after exposure to distilled water) of erythrocytes following a 24 hours incubation as a function of trifluoperazine concentrations (1 – 20 µM). D) Original histogram of forward scatter of erythrocytes treated for 24 hours with DMSO (left panel) or 5 µM (midle panel) or 10 µM (right panel) trifluoperazine. Numbers depict the geometric mean (GeoMean) of the FSC of the different erythrocyte populations. E) Arithmetic means ± SEM (n = 3) of forward scatter without (white bar) and with (black bars) 24 hours treatment with TFP at the indicated concentrations. *(p<0.05), **(p<0.01), ***(p<0.001),****(p<0.0001) indicates significant difference from DMSO.

Fig. 1.

Effect of trifluoperazine on phosphatidylserine exposure, hemolysis and cell volume. A) Original histogram of annexin-V-binding of erythrocytes treated for 24 hours with either DMSO (left panel, control) or with 5 µM (middle panel) or 10 µM (right panel) trifluoperazine, respectively. Numbers depict the geometric mean (GeoMean) of the annexin-V-FITC-dependent fluorescence of the different erythrocyte populations. B) Arithmetic means ± SEM (n = 3) of the percentage of annexin V binding erythrocytes after 24 hours incubation as a function of trifluoperazine concentrations (1 – 20 µM). C) Arithmetic means ± SEM (n = 3) of hemolysis (in % of maximal hemolysis after exposure to distilled water) of erythrocytes following a 24 hours incubation as a function of trifluoperazine concentrations (1 – 20 µM). D) Original histogram of forward scatter of erythrocytes treated for 24 hours with DMSO (left panel) or 5 µM (midle panel) or 10 µM (right panel) trifluoperazine. Numbers depict the geometric mean (GeoMean) of the FSC of the different erythrocyte populations. E) Arithmetic means ± SEM (n = 3) of forward scatter without (white bar) and with (black bars) 24 hours treatment with TFP at the indicated concentrations. *(p<0.05), **(p<0.01), ***(p<0.001),****(p<0.0001) indicates significant difference from DMSO.

Close modal

An extended exposure (24 hours) to 10 µM TFP decreased significantly the average erythrocyte forward scatter whereas incubation of the cells with 5 µM TFP resulted in significant swelling when compared to DMSO-treated erythrocytes (Fig. 1D, E).

Impact of TFP on cytoplasmic Ca2+ concentration

Fluo3 fluorescence was taken as a measure of cytoplasmic Ca2+ concentration ([Ca2+]i). As shown in Fig. 2A, B, exposure to TFP increased the percentage of erythrocytes with enhanced Fluo3 fluorescence, an effect reaching statistical significance after 1 hour at 1 µM TFP. At the highest concentration of TFP (20 µM), intracellular Ca2+ concentration was equal to the maximum calcium load induced by the Ca2+ ionophore ionomycin (0.25 µM; Fig. 2A, B). A short exposure (1 – 6 hours) to low concentrations of TFP increased the average erythrocyte forward scatter pointing to cell swelling, an effect reaching statistical significance at 5 – 15 µM TFP (Fig. 2C). For comparison, the effect of ionomycin (0.25 µM) on Fluo 3 fluorescence and forward scatter (FSC) of the erythrocytes populations is shown (Fig. 2B, C, black bars).

Fig. 2.

Effect of trifluoperazine and Ca2+ ionophore ionomycin on Fluo3 fluorescence and cell volume. A) Original histograms of Fluo3-dependent fluorescence in erythrocytes treated for 6 hours with DMSO (left panel, control), 10 µM trifluoperazine (middle panel) or with 0.25 µM ionomycin (right panel) as a positive control. Numbers depict the geometric mean (GeoMean) of the Fluo-3-dependent fluorescence of the different erythrocyte populations. B,C) Arithmetic means ± SEM (n = 3) of Fluo3-dependent fluorescence (B) and forward scatter (FSC) (C) of erythrocytes following exposure for 1 (open squares), 3 (open triangles) and 6 hours (closed squares) to Ringer solution containing 1 – 20 µM trifluoperazine. For comparison, the respective values following a 6 hours exposure to 0.25 µM ionomycin (black bars) are shown. *(p<0.05), **(p<0.01), ***(p<0.001),****(p<0.0001) indicates significant difference from DMSO.

Fig. 2.

Effect of trifluoperazine and Ca2+ ionophore ionomycin on Fluo3 fluorescence and cell volume. A) Original histograms of Fluo3-dependent fluorescence in erythrocytes treated for 6 hours with DMSO (left panel, control), 10 µM trifluoperazine (middle panel) or with 0.25 µM ionomycin (right panel) as a positive control. Numbers depict the geometric mean (GeoMean) of the Fluo-3-dependent fluorescence of the different erythrocyte populations. B,C) Arithmetic means ± SEM (n = 3) of Fluo3-dependent fluorescence (B) and forward scatter (FSC) (C) of erythrocytes following exposure for 1 (open squares), 3 (open triangles) and 6 hours (closed squares) to Ringer solution containing 1 – 20 µM trifluoperazine. For comparison, the respective values following a 6 hours exposure to 0.25 µM ionomycin (black bars) are shown. *(p<0.05), **(p<0.01), ***(p<0.001),****(p<0.0001) indicates significant difference from DMSO.

Close modal

Fluorescence microscopy experiments, using Fluo 4/AM confirmed the ability of TFP to increase the intracellular Ca2+ concentration in erythrocytes after 1 – 6 hours exposure time. In these experiments, DMSO- as well as TFP-treated erythrocytes showed a normal disc-like shape (Fig. 3A,B). A magnification of the fluorescence image of two erythrocytes treated with 10 µM TFP for 6 hours is illustrated in Figure 3B.

Fig. 3.

Effect of trifluoperazine on Fluo4 fluorescence (Fluorescence microscopy). A) Fluorescence microscopy overlay images of erythrocytes after treatment with DMSO (left panels), 5 µM TFP (middel panels) or 10 µM TFP (right panels) for the indicated time points 1 hour, 3 hours and 6 hours, respectively. Fluo4/AM has been used to detect intracellular Ca2+ content. The white bars represent 10 µm. B) Magnification of the image for 10 µM TFP at 6 hours, left – brightfield image, middle – fluorescence image, right – overlay. The white bars represent 5 µm. Representative images out of 3 independent experiments.

Fig. 3.

Effect of trifluoperazine on Fluo4 fluorescence (Fluorescence microscopy). A) Fluorescence microscopy overlay images of erythrocytes after treatment with DMSO (left panels), 5 µM TFP (middel panels) or 10 µM TFP (right panels) for the indicated time points 1 hour, 3 hours and 6 hours, respectively. Fluo4/AM has been used to detect intracellular Ca2+ content. The white bars represent 10 µm. B) Magnification of the image for 10 µM TFP at 6 hours, left – brightfield image, middle – fluorescence image, right – overlay. The white bars represent 5 µm. Representative images out of 3 independent experiments.

Close modal

Effect of TFP on whole-cell currents

Patch-clamp measurements of whole-cell currents were performed in the presence of 1 and 10 µM TFP. Fig. 4 shows the averaged I/V curves of control measurements and after application of 1 µM TFP (Fig. 4A) or 10 µM TFP (Fig. 4B). While 1 µM TFP did not have any effect on either the inward or outward current, 10 µM TFP significantly decreased the outward current.

Fig. 4.

Effect of trifluoperazine on whole-cell erythrocyte currents. A,B) Arithmetic means ± SEM (n = 3) of the whole cell current as a function of voltage difference across the cell membrane (I/V-curves) in the absence of TFP (blue diamonds) and in the presence of (A) 1 µM TFP (n=11) or (B) 10 µM TFP (n=13, red triangles). Whole cell currents were elicited by voltage steps from -100 mV to 80 mV for 500 ms in 20 mV increments at 5 s intervals, Vh= -30 mV. *(p<0.05) indicates significant difference from controls.

Fig. 4.

Effect of trifluoperazine on whole-cell erythrocyte currents. A,B) Arithmetic means ± SEM (n = 3) of the whole cell current as a function of voltage difference across the cell membrane (I/V-curves) in the absence of TFP (blue diamonds) and in the presence of (A) 1 µM TFP (n=11) or (B) 10 µM TFP (n=13, red triangles). Whole cell currents were elicited by voltage steps from -100 mV to 80 mV for 500 ms in 20 mV increments at 5 s intervals, Vh= -30 mV. *(p<0.05) indicates significant difference from controls.

Close modal

TFP-induced eryptosis is inhibited by exogenous NO, an effect augmented by simultaneous removal of extracellular calcium

A next series of experiments explored whether the TFP-induced cell shrinkage and translocation of phosphatidylserine required entry of extracellular Ca2+. To this end, erythrocytes were incubated for 24 hours in the absence or presence of 1, 5, and 10 µM trifluoperazine in the presence or nominal absence of extracellular Ca2+. As illustrated in Fig. 5A, removal of extracellular Ca2+ even in the presence of 1 mM EGTA did not influence the effect of TFP on the percentage of annexin-V-binding erythrocytes, pointing to a Ca2+-independent induction of eryptosis by TFP. To explore whether TFP-induced eryptosis was sensitive to NO, erythrocytes suspended in Ringer solution were first pre-treated with the NO donor SNP (1 µM) for 2 hours. Subsequently, the cells were either treated with different TFP concentrations (1 - 10 µM) or with DMSO for further 24 hours. TFP-induced eryptosis was significantly inhibited by SNP in the presence (Fig. 5B) as well as absence (Fig. 5C) of calcium. The inhibitory effect was significantly more pronounced by a combination of removal of extracellular Ca2+ and pre-treatment with SNP (Fig. 5D). Compared with the NO-donor SNP (1 µM), addition of the anti-oxidant N-acetyl-L-cysteine (NAC, 1mM) showed less inhibitory effect on TFP-induced annexin-V-binding (Fig. 5E).

Fig. 5.

Impact of extracellular Ca2+ removal and addition of NO donor SNP on trifluoperazine-induced phosphatidylserine exposure and erythrocyte shrinkage. A) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in standard Ringer solution (black squares) or in Ringer lacking Ca2+ (white squares), or lacking Ca2+ and containing 1 mM EGTA (white circles). B) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in standard Ringer solution without (white squares) or with (black triangles) nitroprusside (SNP, 1 µM). C) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in Ca2+ free Ringer solution without (white squares) or with (black triangles) nitroprusside (SNP, 1 µM). D) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in presence of nitroprusside (SNP, 1 µM) in presence (black triangles) or absence (white triangles) of extracellular Ca2+. E) Arithmetic means ± SEM (n = 3) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in standard Ringer solution without (white squares) or with (black squares) N-acetyl-L-cysteine (NAC, 1 mM). *(p<0.05), **(p<0.01), ***(p<0.001), ****(P<0.0001), indicates significant difference from DMSO.

Fig. 5.

Impact of extracellular Ca2+ removal and addition of NO donor SNP on trifluoperazine-induced phosphatidylserine exposure and erythrocyte shrinkage. A) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in standard Ringer solution (black squares) or in Ringer lacking Ca2+ (white squares), or lacking Ca2+ and containing 1 mM EGTA (white circles). B) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in standard Ringer solution without (white squares) or with (black triangles) nitroprusside (SNP, 1 µM). C) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in Ca2+ free Ringer solution without (white squares) or with (black triangles) nitroprusside (SNP, 1 µM). D) Arithmetic means ± SEM (n = 5) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in presence of nitroprusside (SNP, 1 µM) in presence (black triangles) or absence (white triangles) of extracellular Ca2+. E) Arithmetic means ± SEM (n = 3) of annexin-V-binding erythrocytes as a function of TFP concentration following 24 hours exposure to TFP in standard Ringer solution without (white squares) or with (black squares) N-acetyl-L-cysteine (NAC, 1 mM). *(p<0.05), **(p<0.01), ***(p<0.001), ****(P<0.0001), indicates significant difference from DMSO.

Close modal

Blunting of ionomycin induced eryptosis and cell shrinkage by removal of extracellular Ca2+

As positive control, erythrocytes were incubated in Ringer solution or in Ringer solutions without extracellular Ca2+ ±1 mM EGTA. As expected, ionomycin-induced eryptosis and cell shrinkage was completely abrogated by removal of extracellular Ca2+ without or with addition of 1 mM EGTA (Fig. 6).

Fig. 6.

Effects of extracellular Ca2+ removal on ionomycin-induced eryptosis and cell shrinkage. A,B) Representative histograms of (A) annexin-V-binding and (B) forward scatter of erythrocytes following a 3 hours exposure to Ca2+ ionophore ionomycin (0.1 µM) in standard Ringer solution (left panels), in the absence of Ca2+ (middle panels) and in the absence of Ca2+ and presence of 1 mM EGTA (right panels).C,D) Arithmetic means ± SEM (n = 3) of (C) annexin-V-binding and (D) forward scatter of erythrocytes following a 3 hours exposure without (black bars) and with (grey bars) Ca2+ ionophore ionomycin (0.1 µM) in standard Ringer solution (left bars), in the absence of Ca2+ (middle bars) or in the absence of Ca2+ and presence of 1 mM EGTA (right bars), **(P<0.01).

Fig. 6.

Effects of extracellular Ca2+ removal on ionomycin-induced eryptosis and cell shrinkage. A,B) Representative histograms of (A) annexin-V-binding and (B) forward scatter of erythrocytes following a 3 hours exposure to Ca2+ ionophore ionomycin (0.1 µM) in standard Ringer solution (left panels), in the absence of Ca2+ (middle panels) and in the absence of Ca2+ and presence of 1 mM EGTA (right panels).C,D) Arithmetic means ± SEM (n = 3) of (C) annexin-V-binding and (D) forward scatter of erythrocytes following a 3 hours exposure without (black bars) and with (grey bars) Ca2+ ionophore ionomycin (0.1 µM) in standard Ringer solution (left bars), in the absence of Ca2+ (middle bars) or in the absence of Ca2+ and presence of 1 mM EGTA (right bars), **(P<0.01).

Close modal

Reversal of TFP induced inhibition of S-nitrosylation by addition of NO donor sodium nitroprusside (SNP)

One of the non-classical mechanisms of NO signaling proceeds through the formation of S-nitrosylation, a covalent modification of protein cysteine residues [49, 50]. Protein S-nitrosylation can be detected by specific fluorescent labelling with a “fluorescence switch” procedure [48, 51]. We therefore used this technique to evaluate the extent of S-nitrosylation in erythrocytes (Fig. 7A). TFP treatment for 24 hours decreased protein S-nitrosylation, with a significant effect observed at concentrations higher than 2.5 µM (Fig. 7B). We further investigated whether the NO donor SNP could reverse the effect of TFP on S-nitrosylation. SNP pretreatment dissipated the inhibitory effect of 10 µM TFP on S-nitrosylation (Fig. 7B).

Fig. 7.

Effect of trifluoperazine on erythrocyte protein S-nitrosylation. A) Representative images of a fluorescence switch experiment showing protein S-nitrosylation (Bodipy-TMR signal) and total protein (Sypro Ruby signal) from erythrocytes treated with increasing concentrations of TFP for 24 hours, with 1 µM SNP for 26 hours or with 1 µM SNP and 10 µM TFP. 1 mM CysSNO was added as a positive control of protein S-nitrosylation. B) Arithmetic means ± SEM (n = 4) of the ratio of Bodipy-TMR/Sypro Ruby signals in DMSO (white bar), 1 – 10 µM TFP (T, black bars), 1 µM nitroprusside alone (SNP, light grey bar), 1 µM SNP + 10 µM TFP (dark grey bar) and 1 mM S-nitrosocysteine (CysSNO, shaded bar). Representative images out of 4 independent experiments. *(p<0.05) indicates significant difference to DMSO (repeated measures one-way ANOVA with Sidak's multiple comparisons test).

Fig. 7.

Effect of trifluoperazine on erythrocyte protein S-nitrosylation. A) Representative images of a fluorescence switch experiment showing protein S-nitrosylation (Bodipy-TMR signal) and total protein (Sypro Ruby signal) from erythrocytes treated with increasing concentrations of TFP for 24 hours, with 1 µM SNP for 26 hours or with 1 µM SNP and 10 µM TFP. 1 mM CysSNO was added as a positive control of protein S-nitrosylation. B) Arithmetic means ± SEM (n = 4) of the ratio of Bodipy-TMR/Sypro Ruby signals in DMSO (white bar), 1 – 10 µM TFP (T, black bars), 1 µM nitroprusside alone (SNP, light grey bar), 1 µM SNP + 10 µM TFP (dark grey bar) and 1 mM S-nitrosocysteine (CysSNO, shaded bar). Representative images out of 4 independent experiments. *(p<0.05) indicates significant difference to DMSO (repeated measures one-way ANOVA with Sidak's multiple comparisons test).

Close modal

The present observations reveal that trifluoperazine (TFP) triggers cell membrane scrambling, as apparent from phosphatidyserine translocation to the erythrocyte surface. Moreover, TFP triggers hemolysis as evident from increased turbidity of the supernatants harvested from the corresponding erythrocyte suspensions (Fig. 1 A-C). However, somehow surprisingly, incubation with a lower concentration of TFP (5 µM) for short (1 – 6 hours) as well as for long time periods (24 hours) resulted in significant erythrocyte swelling (Fig. 2C and Fig. 1D, E). The mechanism accounting for this cell swelling remains elusive. Putative mechanisms causing cell swelling include inhibition of K+ channels [52]. Along those lines, TFP has been shown to inhibit a variety of K+ channels [53-57]. Cell swelling may in turn affect cytoskeletal architecture [58, 59].

The effect of TFP on cell membrane scrambling was paralleled by an increase of cytoplasmic Ca2+ (Fig. 2A, B and Fig. 3A, B). The effect of 1 µM TFP was small but statistically significant. Although Ca2+ is a well known trigger of cell membrane scrambling [20], TFP-induced phosphatidylserine translocation was not affected by removal of extracellular Ca2+ or by addition of 1 mM EGTA to Ringer solution without extracellular Ca2+ (Fig. 5A) suggesting a Ca2+-independent mechanism triggering phosphatidylserine exposure on the outer membrane leaflet [45]. In contrast, ionomycin-induced eryptosis is expectedly [60] calcium-dependent (Fig. 6A,B). The patch-clamp measurements revealed that TFP failed to increase the inward current (Fig. 4). Those experiments do, however, not rule out the opening of low conductance ion channels. Alternatively, the observed increase of cytosolic Ca2+ concentration may result from an inhibitory effect of TFP on calmodulin [61] which is required for the operation of the erythrocytes’ plasma membrane Ca2+ pump [62]. Calmodulin antagonism could also account for the observed decrease in the outward current as TFP may block Ca2+-stimulated K+ transport in erythrocytes, possibly the Gardos channel, in the concentration range used in our study [63]. However, although it seems likely that some of the observed effects of TFP result from calmodulin antagonism, the fact that eryptotic events are virtually abrogated by a NO donor (nitroprusside) points to an inhibitory effect of TFP on NO synthase. Along those lines, TFP diminishes the S-nitrosylation levels (Fig. 7). Erythrocytes possess a functional NO synthase and are a major source of NO, contributing to the circulating NO pool [64]. In addition, NO synthase inhibitors reduce erythrocytes deformability [65].

TFP further leads to moderate hemolysis. The physiological function of eryptosis is the clearance of defective erythrocytes from circulating blood prior to hemolysis [20]. Phosphatidylserine exposing erythrocytes are rapidly cleared from circulating blood. Timely removal of defective erythrocytes prevents release of hemoglobin, which may cross the renal glomerular filter, precipitate in the acidic lumen of renal tubules, occlude nephrons and thus cause renal failure [66]. In malaria, eryptosis may accomplish elimination of infected erythrocytes thus limiting parasitemia [67].

The clearance of eryptotic erythrocytes from circulating blood may, however, lead to anemia, if the loss of eryptotic erythrocytes exceeds the formation of new erythrocytes by erythropoiesis [20]. Phosphatidylserine exposing erythrocytes may further adhere to the vascular wall [68], stimulate blood clotting [69] and trigger thrombosis [70], effects potentially compromising microcirculation [23, 71, 72]. Excessive eryptosis may thus contribute to anemia and jeopardise microcirculation in several clinical conditions, including iron deficiency [20], dehydration [73], hyperphosphatemia [74], chronic kidney disease (CKD) [75, 76], hemolytic-uremic syndrome [77], diabetes [78], hepatic failure [79], malignancy [20], sepsis [80], sickle-cell disease [20], beta-thalassemia [20], Hb-C and G6PD-deficiency [20], as well as Wilsons disease [81]. In those conditions the eryptotic effect of TFP may be particularly threatening.

One of the central findings of this study points to antagonistic roles of Ca2+ and NO. For the first time, we show that pre-treatment of erythrocytes with the NO donor SNP (1 µM) can significantly inhibit TFP-induced eryptosis, and that this inhibitory effect is augmented by additional removal of extracellular Ca2+. Accordingly, a Ca2+-dependent mechanism counter-regulates the effect of NO.

Plasma levels of free or bound NO are in the 3 nM or 7 µM range, respectively [82]. However, the blood plasma levels of free Ca2+ are within the 1 to 1.5 mM range. There is a strong correlation between the elevation of [Ca2+]i and ROS formation, two cross-talking messengers capable to initiate apoptosis [83]. Interestingly, ROS and in particular superoxide anion reacts with NO diminishing its bioavailability [84]. Thus, TFP-induced accumulation of [Ca2+]i (Fig. 2A, B and Fig. 3A, B) could lead to ROS formation, subsequent destruction of NO and thus induction of eryptosis. In the presence of Ca2+ calmodulin avidly binds to two TFP molecules and thus forces its own inactivation (for review see [85]). Along those lines, TFP-induced accumulation of [Ca2+]i serves to biologically inactivate calmodulin, thus inducing eryptosis. It is known that calmodulin inhibitors induce apoptosis [86]. On the other hand, we also observed a Ca2+-independent induction of eryptosis by TFP (Fig. 5A) which was efficiently inhibited by the addition of exogenous NO (Fig. 5B – C and Fig. 8).

Fig. 8.

Grafical representation of the study´s central findings. I) Eryptosis is mediated by TFP in a Ca2+-dependent and a Ca2+-independent manner. II) Pre-treatment of erythrocytes with the NO donor SNP (1 µM) significantly inhibits TFP-induced eryptosis. III) The inhibitory effect of SNP is augmented by removal of extracellular Ca2+. Abbreviations: Trifluoperazine (TFP), Calcium (Ca2+), Nitric Oxide (NO), Sodium Ni-troprusside (SNP).

Fig. 8.

Grafical representation of the study´s central findings. I) Eryptosis is mediated by TFP in a Ca2+-dependent and a Ca2+-independent manner. II) Pre-treatment of erythrocytes with the NO donor SNP (1 µM) significantly inhibits TFP-induced eryptosis. III) The inhibitory effect of SNP is augmented by removal of extracellular Ca2+. Abbreviations: Trifluoperazine (TFP), Calcium (Ca2+), Nitric Oxide (NO), Sodium Ni-troprusside (SNP).

Close modal

SNP addition did not increase S-nitrosylation levels, but reversed the effect of TFP on S-nitrosylation (Fig. 7). Possibly, in the absence of TFP, the S-nitrosylation is already maximal and cannot be increased further.

In conclusion, TFP triggers eryptosis in a Ca2+-dependent and a Ca2+-independent manner, effects paralleled by a decrease in S-nitrosylation, and sensitive to the inhibitory effect of nitric oxide pretreatment. Furthermore, antagonistic roles of Ca2+ and NO, shown in this study, should deepen our knowledge about calcium- and nitric oxide-associated diseases.

The authors acknowledge the meticulous preparation of the manuscript by Tanja Loch. The study was designed by M.G. The study was mainly financed by M.G. and partly supported by the Deutsche Forschungsgemeinschaft La 315/15 as well as by a grant from CNPq program "science without borders" to Mauro C. Wesseling, process number: 202426/2012-2 (Brasil) as well as by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No 602121 (CoMMiTMenT) to LK, and grants PI12/00875 and PI15/00107 from the Spanish Government (partly funded by FEDER/EDRF) to A.M.-R. Work of R.B. is supported by the Institutional Strategy of the University of Tuebingen (Deutsche Forschungsgemeinschaft, ZUK63) and Open Access Publishing Fund of Tuebingen University.

No conflicts of interest, financial or otherwise, are declared by the authors.

1.
Achour A, Lu W, Arlie M, Cao L, Andrieu JM: T cell survival/proliferation reconstitution by trifluoperazine in human immunodeficiency virus-1 infection. Virology 2003; 315:245-258.
2.
Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA: Trifluoperazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2014; 1:CD010226.
3.
Marques LO, Lima MS, Soares BG: Trifluoperazine for schizophrenia. Cochrane Database Syst Rev 2004:CD003545.
4.
Tardy M, Dold M, Engel RR, Leucht S: Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2014; 7:CD009396.
5.
Molokie RE, Wilkie DJ, Wittert H, Suarez ML, Yao Y, Zhao Z, He Y, Wang ZJ: Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease. Eur J Pharmacol 2014; 723:419-424.
6.
Szabo M, Dulka K, Gulya K: Calmodulin inhibition regulates morphological and functional changes related to the actin cytoskeleton in pure microglial cells. Brain Res Bull 2016; 120:41-57.
7.
Levin RM, Weiss B: Specificity of the binding of trifluoperazine to the calcium-dependent activator of phosphodiesterase and to a series of other calcium-binding proteins. Biochim Biophys Acta 1978; 540:197-204.
8.
Vandonselaar M, Hickie RA, Quail JW, Delbaere LT: Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat Struct Biol 1994; 1:795-801.
9.
Bogdanova A, Makhro A, Wang J, Lipp P, Kaestner L: Calcium in red blood cells-a perilous balance. Int J Mol Sci 2013; 14:9848-9872.
10.
Scharff O, Foder B: Effect of trifluoperazine, compound 48/80, TMB-8 and verapamil on the rate of calmodulin binding to erythrocyte Ca2+-ATPase. Biochim Biophys Acta 1984; 772:29-36.
11.
Pan D, Yan Q, Chen Y, McDonald JM, Song Y: Trifluoperazine regulation of calmodulin binding to Fas: a computational study. Proteins 2011; 79:2543-2556.
12.
Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, Ho CC, Chen CC, Kuo YL, Lee PY, Liu YW, Yen CC, Hsiao M, Lu PJ, Lai JM, Wang LS, Wu CH, Chiou JF, Yang PC, Huang CY: Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 2012; 186:1180-1188.
13.
Eriksson A, Yachnin J, Lewensohn R, Nilsson A: DNA-dependent protein kinase is inhibited by trifluoperazine. Biochem Biophys Res Commun 2001; 283:726-731.
14.
Chen QY, Wu LJ, Wu YQ, Lu GH, Jiang ZY, Zhan JW, Jie Y, Zhou JY: Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. Mol Med Rep 2009; 2:811-817.
15.
Shin SY, Kim CG, Hong DD, Kim JH, Lee YH: Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U87MG glioma cells. Exp Mol Med 2004; 36:380-386.
16.
Shin SY, Choi BH, Kim JR, Kim JH, Lee YH: Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant L1210 mouse leukemia cells. Eur J Pharm Sci 2006; 28:300-306.
17.
Liu S, Han Y, Zhang T, Yang Z: Protective effect of trifluoperazine on hydrogen peroxide-induced apoptosis in PC12 cells. Brain Res Bull 2011; 84:183-188.
18.
Gangopadhyay S, Karmakar P, Dasgupta U, Chakraborty A: Trifluoperazine stimulates ionizing radiation induced cell killing through inhibition of DNA repair. Mutat Res 2007; 633:117-125.
19.
Sullivan GF, Garcia-Welch A, White E, Lutzker S, Hait WN: Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. J Exp Ther Oncol 2002; 2:19-26.
20.
Alzoubi K, Egler J, Abed M, Lang F: Enhanced Eryptosis Following Auranofin Exposure. Cell Physiol Biochem 2015; 37:1018-1028.
21.
Lang F, Qadri SM: Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif 2012; 33:125-130.
22.
Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM: Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003; 285:C1553-C1560.
23.
Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F: Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012; 303:C991-999.
24.
Lang KS, Myssina S, Brand V, Sandu C, Lang PA, Berchtold S, Huber SM, Lang F, Wieder T: Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ 2004; 11:231-243.
25.
Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012; 6:847-856.
26.
Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013; 50:489-495.
27.
Bissinger R, Barking S, Alzoubi K, Liu G, Liu G, Lang F: Stimulation of Suicidal Erythrocyte Death by the Antimalarial Drug Mefloquine. Cell Physiol Biochem 2015; 36:1395-1405.
28.
Briglia M, Fazio A, Faggio C, Lang F: Triggering of Suicidal Erythrocyte Death by Zosuquidar. Cell Physiol Biochem 2015; 37:2355-2365.
29.
Fazio A, Briglia M, Faggio C, Alzoubi K, Lang F: Oxaliplatin Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015; 37:2393-2404.
30.
Lang E, Jilani K, Bissinger R, Rexhepaj R, Zelenak C, Lupescu A, Lang F, Qadri SM: Vitamin D-Rich Diet in Mice Modulates Erythrocyte Survival. Kidney Blood Press Res 2015; 40:403-412.
31.
Officioso A, Alzoubi K, Manna C, Lang F: Clofazimine Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015; 37:331-341.
32.
Peter T, Bissinger R, Enkel S, Alzoubi K, Oswald G, Lang F: Programmed erythrocyte death following in vitro Treosulfan treatment. Cell Physiol Biochem 2015; 35:1372-1380.
33.
Stockinger K, Bissinger R, Bouguerra G, Abbes S, Lang F: Enhanced Eryptosis Following Exposure to Carnosic Acid. Cell Physiol Biochem 2015; 37:1779-1791.
34.
Waibel S, Bissinger R, Bouguerra G, Abbes S, Lang F: Saquinavir Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015; 37:1973-1982.
35.
Zierle J, Bissinger R, Egler J, Lang F: Lapatinib Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015; 37:2275-2287.
36.
Bissinger R, Waibel S, Bouguerra G, Al Mamun Bhuyan A, Abbes S, Lang F: Enhanced Eryptosis Following Exposure to Lopinavir. Cell Physiol Biochem 2015; 37:2486-2495.
37.
Pretorius E, du Plooy JN, Bester J: A Comprehensive Review on Eryptosis. Cell Physiol Biochem 2016; 39:1977-2000.
38.
Shan F, Yang R, Ji T, Jiao F: Vitamin C Inhibits Aggravated Eryptosis by Hydrogen Peroxide in Glucose-6-Phosphated Dehydrogenase Deficiency. Cell Physiol Biochem 2016; 39:1453-1462.
39.
Signoretto E, Laufer SA, Lang F: Stimulating Effect of Sclareol on Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2016; 39:554-564.
40.
Signoretto E, Zierle J, Bissinger R, Castagna M, Bossi E, Lang F: Triggering of Suicidal Erythrocyte Death by Pazopanib. Cell Physiol Biochem 2016; 38:926-938.
41.
Zierle J, Bissinger R, Lang F: Inhibition by Teriflunomide of Erythrocyte Cell Membrane Scrambling Following Energy Depletion, Oxidative Stress and Ionomycin. Cell Physiol Biochem 2016; 39:1877-1890.
42.
Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F: Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol 2003; 14:2750-2757.
43.
Nicolay JP, Liebig G, Niemoeller OM, Koka S, Ghashghaeinia M, Wieder T, Haendeler J, Busse R, Lang F: Inhibition of suicidal erythrocyte death by nitric oxide. Pflugers Arch 2008; 456:293-305.
44.
Lang PA, Kempe DS, Tanneur V, Eisele K, Klarl BA, Myssina S, Jendrossek V, Ishii S, Shimizu T, Waidmann M, Hessler G, Huber SM, Lang F, Wieder T: Stimulation of erythrocyte ceramide formation by platelet-activating factor. J Cell Sci 2005; 118:1233-1243.
45.
Nguyen DB, Wagner-Britz L, Maia S, Steffen P, Wagner C, Kaestner L, Bernhardt I: Regulation of phosphatidylserine exposure in red blood cells. Cell Physiol Biochem 2011; 28:847-856.
46.
Wesseling MC, Wagner-Britz L, Huppert H, Hanf B, Hertz L, Nguyen DB, Bernhardt I: Phosphatidylserine Exposure in Human Red Blood Cells Depending on Cell Age. Cell Physiol Biochem 2016; 38:1376-1390.
47.
Makhro A, Huisjes R, Verhagen LP, Manu-Pereira Mdel M, Llaudet-Planas E, Petkova-Kirova P, Wang J, Eichler H, Bogdanova A, van Wijk R, Vives-Corrons JL, Kaestner L: Red Cell Properties after Different Modes of Blood Transportation. Front Physiol 2016; 7:288.
48.
Tello D, Tarín C, Ahicart P, Bretón-Romero R, Lamas S, Martínez-Ruiz A: A “fluorescence switch” technique increases the sensitivity of proteomic detection and identification of S-nitrosylated proteins. Proteomics 2009; 9:5359-5370.
49.
Martínez-Ruiz A, Araújo IM, Izquierdo-Alvarez A, Hernansanz-Agustín P, Lamas S, Serrador JM: Specificity in S-nitrosylation: a short-range mechanism for NO signaling? Antioxid Redox Signal 2013; 19:1220-1235.
50.
Martinez-Ruiz A, Cadenas S, Lamas S: Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. Free Radic Biol Med 2011; 51:17-29.
51.
Izquierdo-Álvarez A, Martínez-Ruiz A: Thiol redox proteomics seen with fluorescent eyes: the detection of cysteine oxidative modifications by fluorescence derivatization and 2-DE. J Proteomics 2011; 75:329-338.
52.
Lang F, Foller M, Lang K, Lang P, Ritter M, Vereninov A, Szabo I, Huber SM, Gulbins E: Cell volume regulatory ion channels in cell proliferation and cell death. Methods Enzymol 2007; 428:209-225.
53.
Chae YJ, Choi BH, Choi JS, Hahn SJ: Block of Kv4.3 potassium channel by trifluoperazine independent of CaMKII. Neurosci Lett 2014; 578:159-164.
54.
Choi SY, Koh YS, Jo SH: Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine. J Pharmacol Exp Ther 2005; 313:888-895.
55.
Hong DH, Son YK, Li H, Jung ID, Park YM, Jung WK, Kim HS, Choi IW, Park WS: The calmodulin inhibitor and antipsychotic drug trifluoperazine inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. Biochem Biophys Res Commun 2014; 443:321-325.
56.
Ikemoto Y, Yoshida A, Oda M: Blockade by trifluoperazine of a Ca(2+)-activated K+ channel in rat hippocampal pyramidal neurons. Eur J Pharmacol 1992; 216:191-198.
57.
Teisseyre A, Michalak K: The voltage- and time-dependent blocking effect of trifluoperazine on T lymphocyte Kv1.3 channels. Biochem Pharmacol 2003; 65:551-561.
58.
Haussinger D, Stoll B, vom Dahl S, Theodoropoulos PA, Markogiannakis E, Gravanis A, Lang F, Stournaras C: Effect of hepatocyte swelling on microtubule stability and tubulin mRNA levels. Biochem Cell Biol 1994; 72:12-19.
59.
Theodoropoulos PA, Stournaras C, Stoll B, Markogiannakis E, Lang F, Gravanis A, Haussinger D: Hepatocyte swelling leads to rapid decrease of the G-/total actin ratio and increases actin mRNA levels. FEBS Lett 1992; 311:241-245.
60.
Lang KS, Duranton C, Poehlmann H, Myssina S, Bauer C, Lang F, Wieder T, Huber SM: Cation channels trigger apoptotic death of erythrocytes. Cell Death Differ 2003; 10:249-256.
61.
Levin RM, Weiss B: Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. Mol Pharmacol 1977; 13:690-697.
62.
Larsen FL, Vincenzi FF: Calcium transport across the plasma membrane: stimulation by calmodulin. Science 1979; 204:306-309.
63.
Yingst DR, Hoffman JF: Ca-induced K transport in human red blood cell ghosts containing arsenazo III. Transmembrane interactions of Na, K, and Ca and the relationship to the functioning Na-K pump. J Gen Physiol 1984; 83:19-45.
64.
Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax T, Kumara I, Gharini P, Kabanova S, Ozuyaman B, Schnurch HG, Godecke A, Weber AA, Robenek M, Robenek H, Bloch W, Rosen P, Kelm M: Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006; 107:2943-2951.
65.
Bor-Kucukatay M, Wenby RB, Meiselman HJ, Baskurt OK: Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol 2003; 284:H1577-1584.
66.
Harrison HE, Bunting H, Ordway NK, Albrink WS: The Pathogenesis of the Renal Injury Produced in the Dog by Hemoglobin or Methemoglobin. J Exp Med 1947; 86:339-356.
67.
Ghashghaeinia M, Bobbala D, Wieder T, Koka S, Bruck J, Fehrenbacher B, Rocken M, Schaller M, Lang F, Ghoreschi K: Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling. Am J Physiol Cell Physiol 2010; 299:C791-804.
68.
Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012; 302:C644-C651.
69.
Kaestner L, Steffen P, Nguyen DB, Wang J, Wagner-Britz L, Jung A, Wagner C, Bernhardt I: Lysophosphatidic acid induced red blood cell aggregation in vitro. Bioelectrochemistry 2012; 87:89-95.
70.
Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27:414-421.
71.
Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 6:76-82.
72.
Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999; 107:300-302.
73.
Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F: Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013; 37:567-578.
74.
Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F: Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013; 38:42-51.
75.
Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F: Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl) 2014; 92:871-879.
76.
Polak-Jonkisz D, Purzyc L: Ca(2+) influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif 2012; 34:209-210; author reply 210.
77.
Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006; 84:378-388.
78.
Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006; 18:223-232.
79.
Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA: Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015; 61:275-284.
80.
Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007; 85:273-281.
81.
Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13:164-170.
82.
Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J: Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A 1992; 89:7674-7677.
83.
Goldman R, Moshonov S, Zor U: Generation of reactive oxygen species in a human keratinocyte cell line: role of calcium. Arch Biochem Biophys 1998; 350:10-18.
84.
Rubanyi GM, Vanhoutte PM: Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986; 250:H822-827.
85.
Cheung WY: Calmodulin plays a pivotal role in cellular regulation. Science 1980; 207:19-27.
86.
Yokokura S, Yurimoto S, Matsuoka A, Imataki O, Dobashi H, Bandoh S, Matsunaga T: Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma. BMC Cancer 2014; 14:882.

T. Wieder and F. Lang share senior authorship

Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.